Status:
TERMINATED
Antipsychotic Effects on Brain Function in Schizophrenia
Lead Sponsor:
University of California, San Francisco
Collaborating Sponsors:
The Dana Foundation
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18-40 years
Phase:
PHASE4
Brief Summary
The purpose of the study is to determine whether two commonly-prescribed antipsychotic medications (aripiprazole and risperidone) have different effects on brain function and cognition in schizophreni...
Detailed Description
Patients with schizophrenia have significant problems in thinking, referred to as cognitive dysfunction, which make it difficult for them to function well, and have no effective treatment at this time...
Eligibility Criteria
Inclusion
- less than 40 years old;
- currently meet criteria for schizophrenia, schizophreniform disorder or schizoaffective disorder from the DSM-IV-TR;
- require new or changed treatment with antipsychotic medication.
Exclusion
- older than 40 years;
- in current antipsychotic treatment that is satisfactory;
- treatment-refractory psychosis;
- active substance-related disorder;
- clinically-unstable (e.g. acute symptoms requiring emergent or acute-care, including acute suicide risk);
- neurological illness or poorly-controlled medical illness;
- currently taking medications for serious medical illness which have significant interactions with modafinil;
- active pregnancy;
- intelligence less than 70 (on standard test);
- contraindications for fMRI (e.g. claustrophobia, metal foreign bodies, etc.);
- uncorrectable visual acuity impairment.
Key Trial Info
Start Date :
April 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2017
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT01913327
Start Date
April 1 2013
End Date
January 1 2017
Last Update
April 20 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California
San Francisco, California, United States, 94143